Subsequently, the impact of FUS-mediated BBB disruption on the transport of two anticancer agents was examined (doxorubicin and T-DM1) in an orthotopic xenograft model of HER2-positive breast cancer BrM, demonstrating increased uptake and penetration of these compounds [100]. This evidence concerns the gene ERBB2 and breast carcinoma.